Wednesday, April 12, 2006


Viral Hepatitis C - What is Hepatitis C?(NC)-Hepatitis C is an infectious

What is Hepatitis C?

(NC)-Hepatitis C is an infectious virus that is carried in the blood and harms the liver. About 240,000 Canadians are infected, many of whom are unaware that they even have it. The number of people with hepatitis C is increasing in Canada and around the world, primarily among those who share needles and other drug equipment. An estimated 5,000 Canadians - mostly young people - get this virus each year. p>

Although the hepatitis C virus has been around for a long time, it was only identified in 1989. It causes inflammation of the liver, which often progresses to cirrhosis (scarring that makes it difficult for the liver to function normally). Of the estimated 5,000 people that are newly infected each year, up to 70 percent experience no symptoms. For some, symptoms may not show up for 20 or 30 years. In the meantime, they may, unknowingly, be infecting others. That is why it is important to know if you are at risk and how to take preventative action.

If you think you have hepatitis C, or that you may be at risk, visit your doctor and ask for the simple blood test for this disease. For more information, contact a health care professional, and visit Health Canada's Web site at www.healthcanada.ca/hepc.

About The Author

News Canada provides a wide selection of current, ready-to-use copyright free news stories and ideas for Television, Print, Radio, and the Web.

News Canada is a niche service in public relations, offering access to print, radio, television, and now the Internet media, with ready-to-use, editorial "fill" items. Monitoring and analysis are two more of our primary services. The service supplies access to the national media for marketers in the private, the public, and the not-for-profit sectors. Your corporate and product news, consumer tips and information are packaged in a variety of ready-to-use formats and are made available to every Canadian media organization including weekly and daily newspapers, cable and commercial television stations, radio stations, as well as the Web sites Canadians visit most often. Visit News Canada and learn more about the NC services.


Tuesday, April 11, 2006


Interferon - Two Studies Recruiting HCV Patients


Two Studies Recruiting HCV Patients
Sho-saiko-to is the number one liver remedy in Japan. It has been prescribed to over 1.5 million patients (in Japan, doctors medically prescribe certain natural remedies, just like doctors prescribe pharmaceutical drugs in the U.S.). Based on the large body...

Shorter Therapy Effective for Genotypes 2 and 3
Genotypes 2 and 3 are much more responsive to current interferon combination therapies. This report details studies that show a shorter course of treatment might be just as effective as longer courses. Researchers continue to refine treatment protocols for HCV...

Vitamins Suggested During Combination Therapy
A Japanese research study demonstrates benefits of Vitamin E and C supplementation during combination therapy. These vitamins appear to protect cells from damage typically incurred from conventional Hepatitis C therapy....

Magnetic Resonance Imaging (MRI Scan)
Title: Magnetic Resonance Imaging (MRI Scan)Category: Procedures and TestsCreated: 12/31/1997Last Editorial Review: 8/31/2005

Ultrasound
Title: UltrasoundCategory: Procedures and TestsCreated: 12/31/1997Last Editorial Review: 10/15/2005

MedMira Rapid Test
The start of the New Year was accompanied by the European Patent Office granting a patent for a rapid HCV test. Now that the technology is here, let's hope the test proves accurate, with high levels of selectivity and specificity....

Monday, April 10, 2006


Viral Hepatitis C - Indenix is Nearing Phase III for Valopicitabine


Indenix is Nearing Phase III for Valopicitabine
It is always good to see progress with alternatives to current medical therapy for HCV. Even though companies that are working on solutions to be used with interferon are not really offering anything groundbreaking or revolutionary, it does continue the...

SCH 503034 Jumps on the Fast Track
Schering-Plough's oral HCV protease inhibitor, SCH 503034, is in phase II trials, and may make for a better combination with Peg-intron. Check-in with us regularly, as we will be keeping close tabs on this development....

Fatty Liver
Title: Fatty LiverCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 8/29/2005

Hepatitis C Patients Taxing Medical System
Title: Hepatitis C Patients Taxing Medical SystemCategory: Health NewsCreated: 12/31/2005 1:59:00 AMLast Editorial Review: 12/31/2005 1:58:37 AM

Peginterferon - SCH 503034 Jumps on the Fast Track


SCH 503034 Jumps on the Fast Track
Schering-Plough's oral HCV protease inhibitor, SCH 503034, is in phase II trials, and may make for a better combination with Peg-intron. Check-in with us regularly, as we will be keeping close tabs on this development....

Primary Biliary Cirrhosis
Title: Primary Biliary CirrhosisCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 9/17/2005

Tattoos don t disrupt order
shared by mfeed Muskogee Daily Phoenix - The Oklahoma Legislature this session will undoubtedly pass a bill permitting tattoo parlors in the state. A House committee sent a bill to the House floor earlier this week, and language between the House and Senate versions will have to be worked ...... Read more... blink it

Hepatitis C
Title: Hepatitis CCategory: Diseases and ConditionsCreated: 12/31/1997Last Editorial Review: 9/17/2005

Ultrasound
Title: UltrasoundCategory: Procedures and TestsCreated: 12/31/1997Last Editorial Review: 10/15/2005

Shorter Therapy Effective for Genotypes 2 and 3
Genotypes 2 and 3 are much more responsive to current interferon combination therapies. This report details studies that show a shorter course of treatment might be just as effective as longer courses. Researchers continue to refine treatment protocols for HCV...

Sunday, April 09, 2006


Viral Hepatitis C - Antibodies Neutralizing Peginterferon Alfa during Retreatment of


Antibodies Neutralizing Peginterferon Alfa during Retreatment of
New England Journal of Medicine - To the Editor: Peginterferons are widely used to treat chronic hepatitis C virus (HCV) infection, an important cause of liver cirrhosis and hepatocellular carcinoma. 1 , 2 , 3 , 4 We describe a patient who did not have a virologic response to